JD Health (06618)'s third-quarter revenue of 20.017 billion yuan increased 16.9% year-on-year

Zhitongcaijing · 1d ago

According to the Zhitong Finance App, JD Health (06618) announced that for the three months ended September 30, 2026, the group obtained revenue of 20.017 billion yuan, an increase of 16.9% over the previous year; the non-IFRS profit for the period was 1,931 billion yuan, an increase of 1.5% over the previous year.

JD Health continues to strengthen its pharmaceutical and health supply chain capabilities and create full-link solutions for new drug commercialization for partners. As of September 30, 2026, more than 110 pharmaceutical companies have chosen JD Health as their partner to launch new products. In the third quarter, more than 50 new drugs were launched through JD Health, including Yangzijiang Pharmaceutical's innovative drug Paramian®, Jinsei Pharmaceutical's innovative domestic gout drug Jinbeixin®, and Hengrui Pharmaceutical's new drug Hengyi®. In terms of pharmaceutical company cooperation, the company deepens cooperation with partners such as Leo Pharmaceuticals, Genting Xinyao, and Likang Life Technology to jointly explore innovative service models around AI-enabled specialist patient services and chronic disease course management to enhance drug accessibility and patient medication experience.

In the third quarter of 2026, the coverage of the JD Health Drug Purchase and Delivery Service and the scale of partner stores steadily expanded. Through collaboration with partner pharmacies and 24-hour online pharmacist support, the nighttime drug purchase service has been expanded to more than 300 cities across the country. At the same time, JD is upgrading its existing cold chain distribution service in several cities. It can achieve full temperature-controlled distribution and real-time monitoring of hundreds of drugs, and continuously improve the omni-channel drug fulfillment capabilities.

JD Health continues to optimize users' online medical service experience and expand the application of AI in basic health consultation and specialist health management scenarios. In the third quarter of 2026, the number of AI doctors' “Dawei” service users continued to grow rapidly. The average number of AI health service interactions per day increased by more than 5 times over the same period last year, making professional medical consultations more accessible and encouraging users to make more use of online medical and health services. In terms of specialist health management, we have joined forces with multiple specialist expert teams to build and launch famous medical intelligence in the fields of skin, psychology, breathing, and chronic disease metabolism. Through the clinical diagnosis and treatment experience of precipitation experts, smart devices can provide personalized health consultation and long-term continuous follow-up. Users can rely on JD Health's complete “medical, testing, diagnosis, and medicine” business to obtain comprehensive health solutions.